Electronic Health Records Gets Low Scores Among Physicians
A recent survey by AmericanEHR Partners and the AMA of 940 physicians, physician assistants and nurse practitioners showed most physicians are dissatisfied with their EHR systems.
News
Testosterone Therapy Yields No Cardiovascular Harm
Are the benefits of androgen supplementation in older men overstated? Might the risks be understated?
Metformin May Improve Netosis Driven Lupus Activity
Neutrophil extracellular traps (NETs) are first line defense tools used to trap microbial pathogens.
Statins Improve CV risk in RA
Since publication of the Jupiter trial that showed statin effects may include the lowering of C-reactive protein levels and inflammation, there have been several efforts to study the adjunctive effects of statins in rheumatoid arthritis treatment.
International Psoriasis Council Publishes its Research Priorities
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Minority of Nonradiographic-Axial SpA Patients will Progress to Ankylosing Spondylitis
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
CV Risk in RA: Is a New Measurement Tool the Answer?
A new expanded cardiovascular (CV) risk calculator for use in patients with rheumatoid arthritis (RA) has been developed to take into account disease-specific factors that can worsen risk, researchers reported.
Heel Pain, Uveitis, TB, Vitamin D, Hidradenitis: July 2015 top social media news
In July 2015, RheumNow published 73 tweets about impactful news, research and teaching points that I feel will have an impact on the rheumatology community. We had a reach (impressions) of 49,900, 63 mentions, and 1277 visits to RheumNow.com to check out what we publish.
AstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Cymbalta Lawsuit Alleges Downplay of Withdrawal Symptoms
An estimated 250 people have filed lawsuits against Lilly claiming the company failed to warn users of Cymbalta that they may suffer withdrawal symptoms if the drug was stopped abruptly, including suicidal thoughts and electric shock-like sensations.
10 Year Study Identifies Predictors of Skin Progression in Systemic Sclerosis
The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.
Bidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
